Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Total Non-Current Liabilities (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 66.59% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, down 66.59% year-over-year, with the annual reading at $5.0 million for FY2025, 66.59% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $5.0 million at Mereo BioPharma, down from $6.7 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $34.9 million in Q4 2021, with the low at $5.0 million in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $14.9 million, with a median of $14.9 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities decreased 6.75% in 2024, then crashed 66.59% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $34.9 million in 2021, then decreased by 25.42% to $26.0 million in 2022, then crashed by 38.75% to $15.9 million in 2023, then decreased by 6.75% to $14.9 million in 2024, then plummeted by 66.59% to $5.0 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $5.0 million, $6.7 million, and $7.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.